Sage Journals: Discover world-class research

Abstract

Italian

Keywords

Rene policistico autosomico dominante Ipertensione arteriosa Inibitori dell'enzima di conversione Patologia cardiovascolare

Get full access to this article

View all access options for this article.

References

Gabow

P.A.

, Johnson

A.M.

, Kaehny

W.D.

. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int 1992; 341: 1311–9.

Marcelli

, Locatelli

, Aberti

. Hypertension as a factor in chronic renal insufficiency progression in polycystic kidney disease. Nephrol Dial Transplant 1995; 10(Suppl 6): S15–17.

Chapman

A.B.

, Schrier

R.W.

Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991; 11: 653–60.

Gabow

, Schrier

R.W.

Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8: 1292–7.

Fick

G.M.

, Johnson

A.M.

, Hammond

W.S.

, Gabow

P.A.

Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2048–56.

The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46.

Ecder

, Edelstein

C.L.

, Fick-Brosnahan

G.M.

. Progress in Blood Pressure Control. In Autosomal Dominant Polycystic Kidney Disease American Journal of Kidney Diseases, 2000, Vol 36, No 2 (August): 266–71.

Ecder

, Schrier

R.W.

Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194–200.

Kelleher

C.L.

. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 2004; 17: 1029–34.

10.

Zeier

, Geberth

, Schmidt

K.G.

. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3: 1451.

11.

Ecder

, Schrier

R.W.

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009; 5(4): 221–8.

12.

Leier

C.V.

. Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann Intern Med 1984; 100: 683–8.

13.

Timio

. The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: a 10-year follow-up in a five-generation kindred. Clin Nephrol 1992; 37: 245–51.

14.

Sedman

. Autosomal dominant polycystic kidney disease In childhood: a longitudinal study. Kidney Int 1987; 31: 1000–05.

15.

Cadnapaphornchai

M.A.

, McFann

, Strain

J.D.

. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008; 74: 1192–6.

16.

Torres

V.E.

, and Harris

P.C.

Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149–68.

17.

Ivy

D.D.

. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2032–6.

18.

Schrier

R.W.

. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1792–9.

19.

Gabow

P.A.

, Chapman

A.B.

, Johnson

A.M.

. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38(6): 1177–80.

20.

Neumann

, Ligtenberg

, Klein

I.H.

, Blankestijn

P.J.

Pathogenesis and treatment of hypertension in polycystic kidney disease. Curr Opin Nephrol Hypertens 2002; 11: 517–21.

21.

Doulton

T.W.

. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 2006; 24: 939–45.

22.

Torres

V.E.

. Natriuretic response to volume expansion in polycystic kidney disease. Mayo Clin Proc 1989; 64: 509–15.

23.

Griffin

M.D.

. Vascular expression of polycystin. J Am Soc Nephrol 1997; 8: 616–26.

24.

Torres

V.E.

. Vascular expression of polycystin-2. J Am Soc Nephrol 2001; 12: 1–9.

25.

Rizk

, Chapman

A.B.

Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42: 1305.

26.

Chapman

A.B.

Approaches to testing new treatments In autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008; 3: 1197–204.

27.

Ecder

. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am. J Kidney Dis 2000; 35: 427–32.

28.

Chapman

A.B.

. Overt proteinuria and microalbuminuria In autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1349–54.

29.

Zeltner

. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2008; 23: 573–9.

30.

Jafar

T.H.

. The effect of angiotensin-converting enzyme Inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67: 265–71.

31.

Grantham

J.J.

, Chapman

A.B.

, Torres

V.E.

Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148–57.

32.

Ecder

. Diuretics versus angiotensin-converting enzyme inhibitors In autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21: 98–103.

33.

Nutahara

. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005; 99: c18–c23.

34.

Chobanian

A.V.

, Bakris

G.L.

, Black

H.R.

. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560–72.

35.

Chapman

A.B.

, Gabow

P.A.

, Schrier

R.W.

Reversible renal failure associated angiotensin-converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 1991; 115: 769.

36.

Zeier

, Fehrenbach

, Geberth

. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259.

37.

Sarnak

M.J.

, Greene

, Wang

. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342.

38.

Ecder

, Edelstein

C.L.

, Chapman

A.B.

. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999; 14(5): 1113–6.

39.

Schrier

R.W.

. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63: 678–85.

L'ipertensione arteriosa nel Rene Policistico Autosomico Dominante (ADPKD)

Abstract

Keywords

Get full access to this article

References